novo nordisk

DIABETES PIPELINE ANALYSIS – NOVO NORDISK

2017-10-19T23:47:48+00:00

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1 combination product Xultophy®,  which is expected to reach $1.2 billion in 2021.11 In the basal category, Novo Nordisk’s Levemir® has long been second to Sanofi’s Lantus, despite steadily increasing share over time. Hoping to break out in this category, in early 2016, Novo Nordisk launched Tresiba®, their next generation basal insulin to compete against Lantus® and Lantus’s successor Toujeo®. This [...]

DIABETES PIPELINE ANALYSIS – NOVO NORDISK 2017-10-19T23:47:48+00:00